Brought to you by 
Elan, Beyond Genomics ally in Alzheimer's drug discovery
25 Feb 2002
Executive Summary
In its first corporate partnership, Beyond Genomics (systems biology technology) will apply its chemometric and biometric tools in a two-year joint venture with Elan to identify biomarkers and drug targets to diagnose and treat Alzheimer's disease. Elan made a $5mm up-front equity investment in the company.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Joint Venture
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Elan, Beyond Genomics ally in Alzheimer's drug discovery
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice